 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1093858
Dealmaking and Industry Outlook: Neurological Disease
|
Description: |
The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may soon be superseded by new approaches. The key to future success in this therapy area is a better understanding of the underlying biomarkers, genes, and disease pathways that lead to disease. Pharma companies have scoured the ranks of available drug targets, technologies, and innovation in neurological diseases and have executed a plethora of acquisitions and deals. In this report, we categorize more than 300 deals in the neurological disease industry for a 32-month period including 2007, 2008, and the first eight months of 2009. We assess the neurology market and its major players as well as analyze the deals that companies are executing and the business strategies they are deploying to gain future success.
Questions Answered in This Report
Decision Resources Pharmaview analysts forecast that the neurology market will grow to $45.2 billion in 2013.
- Which pharma companies will be the major players in 2013?
- What will account for much of the flux that will be seen in neurology markets from 2008 to 2013?
Analyzing deals opens up a window to a company’s business strategies.
- What do the 340 deals in the neurology industry for 2007, 2008, and the first eight months of 2009 say about pharma companies’ strategies in this therapy area?
- What targets were licensed or optioned?
- What were the largest deals and who were the most prolific dealmakers?
- What merger and acquisition strategies were in play?
Complications can arise when multiple parties hold rights to the same product and companies get overzealous in their partnering activities?
- What almost derailed Elan’s Tysabri collaboration with Biogen Idec?
- Why are Johnson & Johnson and Pfizer now partners on an immunotherapy program for AD?
Too many small biotechs have too few products of unknown quality to entice investors in a tight money market to invest.
- How big of a concern is bankruptcy or liquidation for small neurology companies?
- Which companies have chosen to survive by reverse merger or consolidation?
Companies are scouring early-stage technology opportunities for breakthrough technologies and innovative product candidates.
- Why are disease-specific disease foundations so important?
- What disruptive therapies are in development?
- What technologies are hot?
Researchers must gain a better understanding of disease pathways because interrupting these pathways is the basis of targeted therapeutic intervention.
- What recent gene discoveries and disease pathways have been discovered?
- What new therapeutic approaches might supersede existing therapies in development?
Scope
Expert commentary: Mechanism of action, mitochondria, misfolded proteins, disease pathogenesis, new therapeutic approach, Medivation, Dimebon, Huntington Study Group.
Diseases: Amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), epilepsy, Huntington’s disease (HD), insomnia, migraine, multiple sclerosis (MS), Parkinson’s disease (PD), restless legs syndrome (RLS), stroke.
Therapy area: Market size, top 25 companies, blockbusters, market share, changing franchises, major products, patent expiry, companies gaining and losing the most sales, new genes, new targets and disease pathways, new therapeutic approaches.
Dealmaking: Analysis of more than 300 deals, deal volume, mega-deals valued at more than $1 billion, deals valued at more than $400 million, most-prolific dealmakers, disease-focused nonprofit organizations, dealmaking pitfalls, Big Pharma collaboration, change of control licensing provisions, disease deals, technology deals.
Business strategies: Collaborations, codevelopment, co-commercialization, copromotion, strategic alliances, inlicensing, mergers and acquisitions (M&As), divestment, product acquisitions, patent litigation settlements, marketing agreements, marketed product portfolio acquisitions, brand expansion, international expansion, emerging markets, royalty buyouts, manufacturing agreements, options, mega-mergers, targeted acquisitions, activist investors, liquidation, reverse mergers, consolidation, strengthening franchises.
Targets: Neuronal nicotinic receptors, orexin receptor, beta-amyloid, neuronal potassium channel openers, autophagy pathway targets, alpha-synuclein, neural glial cell markers, selective adhesion molecules, granulocyte-macrophage colony-stimulating factor, fibroblast growth factor receptor 5, interferon-beta, human alpha-fetoprotein, fibroblast growth factor-2, toll-like receptor 9, myelin basic protein, N-type calcium channels, T-type calcium channels, M1 selective muscarinic agonists, Rasrelated guanosine triphosphate-binding proteins, huntingtin, chloride-gated ion channels, presenilin-1 and -2.
Technologies: Immunotherapy, therapeutic vaccines, biologics, biosimilars, stem cell therapy, predictive screening, cell models, new formulations, disease-modifying therapies, peptides, gene therapy, RNA interference, recombinant proteins, biomarkers, glutathione-coated liposomes, nanobodies, Fcfusion proteins, monoclonal antibodies, knock out mice, acetylcholinesterase. |
|
Contents: |
Executive Summary
- Strategic Considerations
- Stakeholder Implications
Changing Opportunities
Spectrum’s Coverage of Central Nervous System Diseases
Neurology Industry: Market Size and Major Players
- Top Players
- Changing Neurology Franchises
- Impact of Patent Expiry
Largest Deals and Dealmakers
- Deal Volume
- Largest Deals
- Most Prolific Dealmakers
- GlaxoSmithKline
- H. Lundbeck
- Elan
- Neurology-Focused Foundations
Big Pharma Collaboration and Pitfalls
Disease and Technology Deals
- Deals By Disease Category
- Deals by Technology
- Antibody Deals
- Recombinant Protein Deals
- Therapeutic Vaccine Deals
Staying Alive—or Not
- Liquidation
- Reverse Merger
- Consolidation
Mergers and Acquisitions
New Genes and Pathways Suggest the Possibility of New Targeted Therapies
- A Potential New Mechanism of Action Involving Mitochondria
- New Genes and Pathway Discoveries
Disruptive Technologies
Industry Outlook |
|
Companies Mentioned |
- 23andMe
- Abbott
- Abiant
- Ablynx
- Acorda Therapeutics
- Actelion
- ActiveSight
- Affi ris
- Albany Molecular Research
- ALS Therapy Development Institute
- Alzheimer’s Drug Discover Foundation
- Ambrx
- Apitope International
- Aptagen
- Arrayit
- Ascend Therapeutics
- Asklepios Biopharmaceutical
- Astellas Pharma
- AstraZeneca
- Aurigene Discovery Technologies
- Banner Alzheimer’s Institute
- Barr Pharmaceuticals
- Bayer Schering Pharma
- Bial
- BioArctic Neuroscience
- BioFocus
- Biogen Idec
- BioMS Medical
- Bionomics
- BioSeek
- Boda Pharmaceutical
- Boehringer Ingelheim
- Breckenridge Pharmaceutical
- Buck Institute for Age Research
- California Stem Cell
- Cambridge Cognition
- Cardiff University
- Cellumen
- Centre Nationale de la Recherche Scientifique
- Cephalon
- Cerebricon
- Charles River Laboratories
- CHDI Foundation
- Chugai
- Cobalt Pharmaceuticals
- Collaborative Drug Discovery
- CoMentis
- Dalton Chemical Laboratories
- DanioLab
- Dr. Reddy’s Laboratories
- Duramed
- Edunn Biotechnology
- Eisai
- Elan
- Eli Lilly
- Evotec
- Fast Forward
- Forest
- Genentech
- Genzyme
- GlaxoSmithKline
- GlobalStem
- Globepan Resources
- Hamilton Pharmaceuticals
- Harvard Medical School
- H. Lundbeck
- Huntington Study Group
- Hypnion
- Immuno-Biological Laboratories
- Ingenuity Systems
- Institut Pasteur de Lille
- Intellect Neurosciences
- Invitrogen
- Ipsen
- Janssen Alzheimer Immunotherapy
- Johns Hopkins University
- Johnson & Johnson
- Jubilant Biosys
- Kali Laboratories
- LifeHealth
- Lundbeck
- M’s Science
- Meda
- Medical Research Council
- Medivation
- Mental Health Research Institute of Melbourne
- Merck & Co.
- Merck KGaA
- Merck Serono
- Michael J. Fox Foundation
- Microbix Biosystems
- Millipore
- Mitsubishi Tanabe Pharma
- MultiCell Technologies
- Myelin Repair Foundation
- Mylan Laboratories
- Neuralstem
- Neuren Pharmaceuticals
- Neurobiological Technologies
- NeuroSearch
- Northwestern University
- Novacea
- NovaMed Pharmaceuticals
- NovaQuest
- Novartis
- Noxxon Pharma
- Oligomerix
- Omeros
- Opexa Therapeutics
- Orion
- Otsuka
- Ovation Pharmaceuticals
- P2D Biosciences
- Parexel
- Parkinson’s Institute
- Peptimmune
- Pfi zer
- Pharmatrophix
- Phytopharm
- Portola Pharmaceuticals
- Prasco Laboratories
- Q Therapeutics
- RemeGenix
- Royalty Pharma
- Salk Institute
- Samaritan Pharmaceuticals
- Sanofi -Aventis
- Sepracor
- Serenex
- SGC Pharma
- Shanghai Institute for Biological Sciences
- Simcere Pharmaceutical
- Solvay
- Stem Cell Sciences
- Summit
- Takeda
- Targacept
- Teikoku Pharma
- Teva
- Texas Institute for Genomic Medicine
- TorreyPines Therapeutics
- Transcept Pharmaceuticals
- UCB
- University of Cambridge
- Valeant Pharmaceuticals
- Varinel
- Vernalis
- Vertex
- Vitae Pharmaceuticals
- Washington University
- Watson Pharmaceuticals
- Wyeth
- XenoPort
- ZymoGenetics |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/1093858
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 17/02/2012 06:15:16 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Dealmaking and Industry Outlook: Neurological Disease
|
|
Web Address: |
http://www.researchandmarkets.com/reports/1093858
|
|
Office Code: |
|
OC8IHINLSNNSS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€1,735.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€3,471.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 17/02/2012 06:15:16
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
